INFERIOR OUTCOMES OF BASILIXIMAB COMPARE TO ANTI-THYMOCYTE GLOBULIN INDUCTION THERAPY IN KIDNEY TRANSPLANTATION WITH WEAK PRETRANSPLANT DONOR SPECIFIC ANTI-HLA ANTIBODY. Issue 3 (September 2020)